Drug Pricing

biosimilars

The Biosimilar Promise

Biosimilars Often Reduce Prices by 50 Percent or More

Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden  | October 1, 2024 READ PDF Executive Summary   In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even ...
Commentary

Learn how PBMs pocket savings intended for patients

How Long Can Pharmacy Benefit Managers Go Unchecked?

Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Blog

Learn how drug price controls hurt patients, innovation

Senator Sanders’ Price Controls Will Harm Patients

In a patently politicized press release, Senator Bernie Sanders (I-VT) who is  Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary

Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.

Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
Commentary

Learn why drug price controls don't work

The Expected Consequences Of Price Controls

The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Commentary

Learn why drug price controls don't work

Don’t Buy Kamala Harris’ Anti-Price Gouging Plan

That may sound like standard progressive fare. But the means by which she’d try to achieve those goals is a scheme of price controls that could destroy entire sectors of the U.S. economy. Read the full article at Forbes
Commentary

Read the latest on Biden administration's drug price controls

Drug Price Controls Underperform, Unworkable

According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Commentary

Read the latest about the problems with PBMs

Insulin Lawsuits Obscure A Dirty Business

The plaintiffs say they’re fighting for patients. They’re less forthcoming about the fact that they’ve profited handsomely from the system they’re now decrying. For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacy benefit managers extract from drug makers when negotiating over ...
Commentary

Read the latest about VP Harris' healthcare platform

Harris commits to worst of Biden healthcare policies

One proposal Harris has explicitly backed would enshrine President Joe Biden’s enhanced Obamacare subsidies, which are slated to expire in 2025. “Republicans want to let those credits expire, increasing premiums,” the Democratic platform asserts. “Democrats will fight to make them permanent.” Read the full article at the Washington Examiner
Commentary

This Bipartisan Bill Would Upend America’s Pharmaceutical Industry

Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
biosimilars

The Biosimilar Promise

Biosimilars Often Reduce Prices by 50 Percent or More

Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden  | October 1, 2024 READ PDF Executive Summary   In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even ...
Commentary

Learn how PBMs pocket savings intended for patients

How Long Can Pharmacy Benefit Managers Go Unchecked?

Last week, a House subcommittee held a hearing on pharmacy benefit managers and their impact on the prices patients pay for prescription drugs. The hearing speaks to voters’ concerns. Republicans and Democrats alike have identified the cost of prescription drugs as their No. 2 health care concern, according to polling ...
Blog

Learn how drug price controls hurt patients, innovation

Senator Sanders’ Price Controls Will Harm Patients

In a patently politicized press release, Senator Bernie Sanders (I-VT) who is  Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary

Drug Companies Are Embracing Direct-To-Consumer Sales. That’s A Win For Patients.

Fortunately, that’s starting to change. In recent months, drug companies Pfizer and Eli Lilly have begun rolling out direct-to-consumer programs that let patients purchase basic prescriptions remotely. This development is a huge win for patients. Not only are direct-to-consumer offerings more convenient. They can also provide a jolt of competition ...
Commentary

Learn why drug price controls don't work

The Expected Consequences Of Price Controls

The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Commentary

Learn why drug price controls don't work

Don’t Buy Kamala Harris’ Anti-Price Gouging Plan

That may sound like standard progressive fare. But the means by which she’d try to achieve those goals is a scheme of price controls that could destroy entire sectors of the U.S. economy. Read the full article at Forbes
Commentary

Read the latest on Biden administration's drug price controls

Drug Price Controls Underperform, Unworkable

According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Commentary

Read the latest about the problems with PBMs

Insulin Lawsuits Obscure A Dirty Business

The plaintiffs say they’re fighting for patients. They’re less forthcoming about the fact that they’ve profited handsomely from the system they’re now decrying. For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacy benefit managers extract from drug makers when negotiating over ...
Commentary

Read the latest about VP Harris' healthcare platform

Harris commits to worst of Biden healthcare policies

One proposal Harris has explicitly backed would enshrine President Joe Biden’s enhanced Obamacare subsidies, which are slated to expire in 2025. “Republicans want to let those credits expire, increasing premiums,” the Democratic platform asserts. “Democrats will fight to make them permanent.” Read the full article at the Washington Examiner
Commentary

This Bipartisan Bill Would Upend America’s Pharmaceutical Industry

Vice President Kamala Harris and Minnesota Governor Tim Walz have pivoted hard to the center in recent weeks in their bid for the White House. But their records indicate that they’d launch even more government intervention in the healthcare market. Harris was the most progressive member of the Senate during ...
Scroll to Top